Gilead Q2 Sales Rise 8%, But Acquisition Charges Drive Quarterly Loss

What happened

Gilead Sciences reported second-quarter product sales that rose 8% year-over-year, beating Wall Street estimates, driven by double-digit gains in its HIV drug portfolio. However, the company posted a quarterly GAAP loss, largely due to approximately $11.5 billion in acquired in-process research and development (IPR&D) charges related to recent acquisitions including Arcellx, Tubulis, and Ouro. The operating business remained healthy, with HIV sales continuing to show strength, confirming the franchise's cash-flow durability. The GAAP loss was well-telegraphed by management, and the sales beat suggests underlying demand trends are solid. This result keeps the investment thesis on track, as the loss is expected to be non-recurring and the focus remains on Yeztugo's commercial ramp and upcoming FDA catalysts.

Implication

The Q2 results underscore that acquisition accounting noise is temporarily obscuring a healthy underlying business, with HIV sales beating expectations. Management had telegraphed the loss, so the focus shifts to Yeztugo's commercial ramp and the upcoming BIC/LEN FDA decision on August 27. The sales beat and HIV durability support the base-case value of $135, while the loss is a known, non-recurring event. If Yeztugo continues to scale and regulatory catalysts hit, forward earnings power will reassert against a moderate P/E of 16.8x. We maintain our POTENTIAL BUY rating with conviction, watching for utilization metrics and charge containment in upcoming disclosures.

Thesis delta

No change to the investment thesis. The reported Q2 loss was expected and does not alter the view that HIV cash flows are durable and the acquisition charges are transitory. The sales beat provides incremental confidence in the base case, reinforcing the belief that Yeztugo and pipeline catalysts will drive re-rating.